AAV Vectors in Gene Therapy Clinical Trials
AAV Vectors in Gene Therapy Clinical Trials
Eurofins experts Vikas Singh and Thomas Beadnell dive deep into the promising world of Adeno-Associated Virus (AAV) vectors in gene therapy.
Gene therapy offers groundbreaking solutions by delivering genetic material to correct or compensate for flawed proteins. While AAV vectors have shown significant potential due to their improved safety profile and tissue specificity, challenges remain—particularly when it comes to managing immune responses.
In this comprehensive article, Vikas and Thomas explore:
-
The growing role of AAV vectors in gene replacement therapies
-
The critical challenge of pre-existing immune responses
-
The pivotal use of ELISpot assays to detect low-frequency T cell responses and their importance in clinical trials
-
Strategies to refine AAV-based therapies, enhancing patient safety and outcomes
Why It Matters: As gene therapy advances, understanding immune responses is vital for success. Tools like the ELISpot assay are paving the way for more precise patient screening, ultimately improving safety and efficacy in clinical trials.
Dive into the full article to learn more about the innovative research that’s shaping the future of gene therapy.